A total of 613 (19.3%), 721 (22.7%), and 1,843 (58.0%) patients had stage 1, stage 2, and stage 3 S-AKI, respectively
However, oral weight-loss medications do exist: oral Wegovy (semaglutide) was approved in late 2025, and Foundayo (orforglipron), an oral GLP-1 pill from Eli Lilly, was FDA-approved in April 2026
Skipping a week reduces your medication's effectiveness and may slow your weight loss progress, though it won't reverse previous results
S., Sirlin, C
Participants were randomized 2:1 to 68 weeks of once-weekly subcutaneous semaglutide 2.4 mg or placebo, both alongside lifestyle intervention
Psychological Health, Well-Being, and the Mind-Heart-Body Connection: AHA Scientific Statement